

10/510020
DT04 Rec'd PCT/PTO 07 OCT 2004

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all earlier versions of claims in the application.

1. (Currently Amended) A method for the treatment of a symptom of a disorder or condition associated with sensorimotor gating deficits, which comprises administering to a mammal in need of the treatment an effective amount of ~~Use of an~~ alfa2-adrenoceptor antagonist, or ~~a~~ its pharmaceutically acceptable ester or salt thereof, said alfa2-adrenoceptor antagonist being selective for the alfa2C-adrenoceptor subtype ~~, in the manufacture of a pharmaceutical for the treatment of symptoms of disorders and conditions associated with sensorimotor gating deficits.~~

2. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is hallucination, delusion, parathymia, agitation, psychotic cognitive impairment, social withdrawal and/or withdrawal symptom associated with cessation of cigarette smoking or alcohol or drug abuse.

3. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is hallucination.

4. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is delusion.

5. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is parathymia.

6. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is agitation,

7. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is psychotic cognitive impairment.

8. (Currently Amended) A method ~~The use~~ according to claim 1, wherein the symptom is social withdrawal.

9. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 8~~, wherein the disorder or condition is schizophrenia, obsessive compulsive disorder, Tourette's syndrome, blepharospasm and other focal dystonias, temporal lobe epilepsy with psychosis, drug-induced psychosis, Huntington's disease, Parkinson's disease, disorder caused by fluctuation of the levels of sex hormones or panic disorder.

10. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 8~~, wherein the disorder is schizophrenia.

11. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 8~~, wherein the disorder is obsessive compulsive disorder.

12. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 8~~, wherein the disorder is Tourette's syndrome.

13. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 12~~, wherein the administering of the alpha2-adrenoceptor antagonist selective for the alpha2C-adrenoceptor is combined with the administering of other psychiatric medication.

14. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 13~~, wherein the mammal is a human.

15. (Currently Amended) A method ~~The use~~ according to claim 1 ~~any one of claims 1 to 8 or 13~~, wherein the mammal is an animal.